Back to Search Start Over

Thioredoxin-1 augments wound healing and promote angiogenesis in a murine ischemic full-thickness wound model.

Authors :
Saad I
Fournier CT
Wilson RL
Lakshmanan R
Selvaraju V
Thirunavukkarasu M
Alexander Palesty J
McFadden DW
Maulik N
Source :
Surgery [Surgery] 2018 Nov; Vol. 164 (5), pp. 1077-1086. Date of Electronic Publication: 2018 Aug 18.
Publication Year :
2018

Abstract

Background: Nonhealing wounds are a continuing health problem in the United States. Overproduction of reactive oxygen species is a major causative factor behind delayed wound healing. Previously we reported that thioredoxin-1 treatment could alleviate oxidative stress under ischemic conditions, such as myocardial infarction and hindlimb ischemia. In this study, we explored the potential for thioredoxin-1 gene therapy to effectively aid wound healing through improved angiogenesis in a murine ischemic wound model.<br />Methods: Full-thickness, cutaneous, ischemic wounds were created in the dorsum skin flap of 8- to 12-week-old CD1 mice. Nonischemic wounds created lateral to the ischemic skin flap served as internal controls. Mice with both ischemic wounds and nonischemic wounds were treated with Adeno-LacZ (1 × 10 <superscript>9</superscript> pfu) or Adeno-thioredoxin-1 (1 × 10 <superscript>9</superscript> pfu), injected intradermally around the wound. Digital imaging was performed on days 0, 3, 6, and 9 to assess the rate of wound closure. Tissue samples collected at predetermined time intervals were processed for immunohistochemical analysis.<br />Results: No significant differences in wound closure were identified among the nonischemic wounds control, nonischemic wounds-LacZ, and nonischemic wounds-thioredoxin-1 groups. Hence, only mice with ischemic wounds were further analyzed. The ischemic wounds-thioredoxin-1 group had significant improvement in wound closure on days 6 and 9 after surgery compared with the ischemic wounds control and ischemic wounds-LacZ groups. Immunohistochemical analysis indicated increased thioredoxin-1, vascular endothelial cell growth factor, and β-catenin levels in the ischemic wounds-thioredoxin-1 group compared with the ischemic wounds control and ischemic wounds-LacZ groups, as well as increased capillary density and cell proliferation, as represented by Ki-67 staining.<br />Conclusion: Taken together, thioredoxin-1 gene therapy promotes vascular endothelial cell growth factor signaling and re-epithelialization and activates wound closure in mice with ischemic wounds.<br /> (Copyright © 2018 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1532-7361
Volume :
164
Issue :
5
Database :
MEDLINE
Journal :
Surgery
Publication Type :
Academic Journal
Accession number :
30131176
Full Text :
https://doi.org/10.1016/j.surg.2018.05.045